TW200505453A - Non-nucleoside reverse transcriptase inhibitors - Google Patents

Non-nucleoside reverse transcriptase inhibitors

Info

Publication number
TW200505453A
TW200505453A TW093107263A TW93107263A TW200505453A TW 200505453 A TW200505453 A TW 200505453A TW 093107263 A TW093107263 A TW 093107263A TW 93107263 A TW93107263 A TW 93107263A TW 200505453 A TW200505453 A TW 200505453A
Authority
TW
Taiwan
Prior art keywords
formula
reverse transcriptase
compounds
transcriptase inhibitors
nucleoside reverse
Prior art date
Application number
TW093107263A
Other languages
English (en)
Inventor
James Patrick Dunn
Brian William Dymock
Taraneh Mirzadegan
Eric Brian Sjogren
Steven Swallow
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TW200505453A publication Critical patent/TW200505453A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
TW093107263A 2003-03-24 2004-03-18 Non-nucleoside reverse transcriptase inhibitors TW200505453A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45714403P 2003-03-24 2003-03-24

Publications (1)

Publication Number Publication Date
TW200505453A true TW200505453A (en) 2005-02-16

Family

ID=33098202

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093107263A TW200505453A (en) 2003-03-24 2004-03-18 Non-nucleoside reverse transcriptase inhibitors

Country Status (13)

Country Link
US (1) US7189718B2 (zh)
EP (1) EP1608629A1 (zh)
JP (1) JP4485520B2 (zh)
KR (1) KR20050119652A (zh)
CN (1) CN100469769C (zh)
AR (1) AR043674A1 (zh)
AU (1) AU2004224191A1 (zh)
BR (1) BRPI0408704A (zh)
CA (1) CA2518823A1 (zh)
MX (1) MXPA05010081A (zh)
RU (1) RU2344128C2 (zh)
TW (1) TW200505453A (zh)
WO (1) WO2004085406A1 (zh)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CN1934092A (zh) * 2004-03-23 2007-03-21 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
CN1942449A (zh) * 2004-04-15 2007-04-04 弗·哈夫曼-拉罗切有限公司 制备哒嗪酮化合物的方法
WO2006040527A1 (en) * 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423042D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Chemical process
JP2008534456A (ja) * 2005-03-24 2008-08-28 エフ.ホフマン−ラ ロシュ アーゲー ヘテロ環式逆転写酵素インヒビターとしての1,2,4−トリアゾール−5−オン化合物
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
AU2006298853A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag NNRT inhibitors
KR20080056220A (ko) 2005-10-19 2008-06-20 에프. 호프만-라 로슈 아게 페닐-아세트아마이드 nnrt 저해제
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
AU2007286345B2 (en) * 2006-08-16 2012-03-08 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP2010522706A (ja) 2007-03-29 2010-07-08 エフ.ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤
AU2008235549A1 (en) * 2007-04-09 2008-10-16 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
JP5431305B2 (ja) 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン2受容体アンタゴニストとしての4−アルコキシピリダジン誘導体
AU2008240729B2 (en) 2007-04-23 2012-08-23 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
MX2009012704A (es) * 2007-05-30 2009-12-08 Hoffmann La Roche Inhibidores de transcriptasa inversa de no nucleosidos.
BRPI0813404A2 (pt) * 2007-06-22 2014-12-30 Hoffmann La Roche Derivados de uréia e carbamato como inibidores de transcriptase reversa de não-nucleosídeo
MX2010005070A (es) 2007-11-15 2010-05-24 Angeletti P Ist Richerche Bio Derivados de piridazinona como inhibidores de parp.
WO2009067166A2 (en) 2007-11-20 2009-05-28 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
US8877816B2 (en) * 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
MX2010006397A (es) * 2007-12-21 2010-07-05 Hoffmann La Roche Compuestos heterociclicos antivirales.
DK2307374T3 (en) 2008-07-31 2017-05-01 Janssen Pharmaceutica Nv PIPERAZIN-1-YLTRIFLUORMETHYL-SUBSTITUTED PYRIDINES AS QUICK DISSOCATING DOPAMIN-2 RECEPTOR ANTAGONISTS
US8299055B2 (en) 2008-10-02 2012-10-30 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and the use thereof
EA024804B1 (ru) 2010-03-30 2016-10-31 Мерк Кэнэда Инк. Ненуклеозидные ингибиторы обратной транскриптазы, композиции, их содержащие, и их применение
CN102731410B (zh) * 2012-07-06 2014-07-30 山东大学 一种哒嗪类hiv-1逆转录酶抑制剂的制备与应用
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP3125894B1 (en) 2014-04-01 2020-09-09 Merck Sharp & Dohme Corp. Prodrugs of hiv reverse transcriptase inhibitors
ES2924257T3 (es) 2016-10-18 2022-10-05 Madrigal Pharmaceuticals Inc Métodos de tratar trastornos hepáticos o trastornos lipídicos con un agonista de THR-beta
CN109053693B (zh) * 2018-09-20 2021-02-05 顺毅股份有限公司 哒嗪胺类化合物的制备及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4949314A (en) 1966-08-16 1990-08-14 The United States Of America As Represented By The Secretary Of The Navy Method and means for increasing echo-ranging-search rate
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4780480A (en) 1983-07-14 1988-10-25 Syntex (U.S.A.) Inc. Aroyl benzofuran and benzothiophene acetic and propionic acids
GB8327880D0 (en) 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU622926B2 (en) 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5489697A (en) 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
BR9509024A (pt) 1994-09-26 1997-09-30 Shionogi & Co Derivados de imidazol
WO1996024343A1 (en) 1995-02-10 1996-08-15 Smithkline Beecham Corporation Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection
WO1996025171A1 (en) 1995-02-16 1996-08-22 F.Hoffmann-La Roche Ag Inhibition of angiogenesis using interleukin-12
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
IL117574A0 (en) 1995-04-03 1996-07-23 Bristol Myers Squibb Co Processes for the preparation of cyclobutanone derivatives
AU6480796A (en) 1995-06-30 1997-02-05 Smithkline Beecham Corporation Use of stat 6 sh2 domain specific compounds to treat allergic reactions
JPH10512585A (ja) 1995-06-30 1998-12-02 スミスクライン・ビーチャム・コーポレイション 赤血球形成を増強するためのstat 5 sh2領域特異性化合物の使用
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
HUP0101595A3 (en) * 1998-04-27 2002-12-28 Inst Curie 3-(amino- or aminoalkyl)pyridinone derivatives, process for producing them, use of them for producing pharmaceutical compositions suitable for treating hiv related diseases and pharmaceutical compositions
AU4884701A (en) 2000-05-12 2001-11-20 Kissei Pharmaceutical Co. Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and usethereof
GB0024795D0 (en) 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
CZ305099B6 (cs) 2001-04-10 2015-05-06 Pfizer Inc. Derivát pyrazolu, způsoby a meziprodukty pro výrobu, farmaceutická kompozice s jeho obsahem a jeho lékařské aplikace, zejména k léčení infekcí HIV
EP1403255A4 (en) 2001-06-12 2005-04-06 Sumitomo Pharma INHIBITORS OF RHO KINASE

Also Published As

Publication number Publication date
KR20050119652A (ko) 2005-12-21
BRPI0408704A (pt) 2006-03-07
AU2004224191A1 (en) 2004-10-07
MXPA05010081A (es) 2005-11-23
US20040198736A1 (en) 2004-10-07
CN1764649A (zh) 2006-04-26
RU2005132630A (ru) 2006-07-27
JP4485520B2 (ja) 2010-06-23
JP2006521310A (ja) 2006-09-21
US7189718B2 (en) 2007-03-13
CA2518823A1 (en) 2004-10-07
WO2004085406A1 (en) 2004-10-07
EP1608629A1 (en) 2005-12-28
CN100469769C (zh) 2009-03-18
RU2344128C2 (ru) 2009-01-20
AR043674A1 (es) 2005-08-03

Similar Documents

Publication Publication Date Title
TW200505453A (en) Non-nucleoside reverse transcriptase inhibitors
TW200505441A (en) Non-nucleoside reverse transcriptase inhibitorsⅠ
CR20210627A (es) Derivados de benzisoxazol sulfonimada
MX2010005292A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
IL180495A (en) Benzyl triazolone compounds as non-nucleotide reverse transcriptase inhibitors
MX2009005881A (es) Derivados de 2-(piperidin-4-il)-4-fenoxi o fenilamino-pirimidina como inhibidores de la transcriptasa inversa no nucleosida.
WO2008132138A9 (en) AMINOPYRIMIDINE DERIVATIVES DISUBSTITUTED IN 4 AND 6
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
NO20050514L (no) Sammensetning og antiviral aktivitet til substituerte azaindoloksoeddikpiperazinderivater
EA200970572A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
PL366726A1 (en) 4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
HUP0401740A2 (hu) N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
MX2022016405A (es) Análogos de nucleósido de 1¿-ciano y usos de estos.
PE20040937A1 (es) Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4)
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
MX2021016149A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
DE60036862D1 (de) Synergistische hemmung von viralreplikation durch langkettigen kohlenwasserstoffe und nucleosid-analoge
DE60318874D1 (en) Pyrazolderivate
EA200601687A1 (ru) Тетрагидроизохинолиновые и тетрагидробензазепиновые производные (варианты), фармацевтическая композиция и фармацевтический набор, лекарственное и эталонное средство для тест-систем на их основе, способ лечения и профилактики заболевания, при котором благоприятна понижающая регуляция или ингибирование экспрессии или функции рецептора igf-1
MX2009010932A (es) Inhibidores no nucleosidos de transcriptasa inversa.
NO20051833L (no) 4-(3,5-dicyanofenoksy)pyrazolderivater for anvendelse som transkriptasemodulatorer ved behandling av IA HIV.